Tenaya Therapeutics Inc. (TNYA)
Tenaya Therapeutics Statistics
Share Statistics
Tenaya Therapeutics has 162.63M shares outstanding. The number of shares has increased by 107.07% in one year.
Shares Outstanding | 162.63M |
Shares Change (YoY) | 107.07% |
Shares Change (QoQ) | 105.23% |
Owned by Institutions (%) | 50.66% |
Shares Floating | 134.13M |
Failed to Deliver (FTD) Shares | 20.1K |
FTD / Avg. Volume | 0.6% |
Short Selling Information
The latest short interest is 10.82M, so 6.66% of the outstanding shares have been sold short.
Short Interest | 10.82M |
Short % of Shares Out | 6.66% |
Short % of Float | 7.8% |
Short Ratio (days to cover) | 4.51 |
Valuation Ratios
The PE ratio is -1.09 and the forward PE ratio is -0.62. Tenaya Therapeutics's PEG ratio is 0.05.
PE Ratio | -1.09 |
Forward PE | -0.62 |
PS Ratio | 0 |
Forward PS | 0.1 |
PB Ratio | 1.31 |
P/FCF Ratio | -1.33 |
PEG Ratio | 0.05 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Tenaya Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.22, with a Debt / Equity ratio of 0.15.
Current Ratio | 4.22 |
Quick Ratio | 4.22 |
Debt / Equity | 0.15 |
Debt / EBITDA | -0.12 |
Debt / FCF | -0.15 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $0 |
Profits Per Employee | $-1.15M |
Employee Count | 97 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -88.63% in the last 52 weeks. The beta is 2.99, so Tenaya Therapeutics's price volatility has been higher than the market average.
Beta | 2.99 |
52-Week Price Change | -88.63% |
50-Day Moving Average | 0.67 |
200-Day Moving Average | 1.87 |
Relative Strength Index (RSI) | 42.98 |
Average Volume (20 Days) | 3.34M |
Income Statement
Revenue | n/a |
Gross Profit | 0 |
Operating Income | -115.95M |
Net Income | -111.13M |
EBITDA | -115.95M |
EBIT | n/a |
Earnings Per Share (EPS) | -1.31 |
Balance Sheet
The company has 4.32M in cash and 13.61M in debt, giving a net cash position of -9.29M.
Cash & Cash Equivalents | 4.32M |
Total Debt | 13.61M |
Net Cash | -9.29M |
Retained Earnings | -514.41M |
Total Assets | 119.94M |
Working Capital | 51.4M |
Cash Flow
In the last 12 months, operating cash flow was -90.5M and capital expenditures -1.02M, giving a free cash flow of -91.53M.
Operating Cash Flow | -90.5M |
Capital Expenditures | -1.02M |
Free Cash Flow | -91.53M |
FCF Per Share | -1.08 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
TNYA does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for TNYA is $5.5, which is 1022.4% higher than the current price. The consensus rating is "Buy".
Price Target | $5.5 |
Price Target Difference | 1022.4% |
Analyst Consensus | Buy |
Analyst Count | 5 |
Scores
Altman Z-Score | -7.03 |
Piotroski F-Score | 1 |